Efficacy of Two-Weekly Nanoparticle Albumin-Bound Paclitaxel as Neoadjuvant Chemotherapy for Breast Cancer

Abstract

<b>Aim:</b> Compare the two-weekly regimens of nanoparticle albumin-bound paclitaxel (nab-P) with solvent-based paclitaxel (sb-P) as neoadjuvant chemotherapy for breast cancer. <b>Materials & methods:</b> Patients (n = 162) with operable early breast cancer received four cycles of dose-dense epirubicin and cyclophosphamide followed by four two-weekly cycles of nab-P (n = 83) or sb-P (n = 79), with trastuzumab when needed. <b>Results:</b> Across all the patients, the ypT0 ypN0 and ypT0/is ypN0 pathological complete response rates in the nab-P group were not superior to those in the sb-P group. However, pathological complete response rates for triple-negative breast cancer were significantly better with nab-P than with sb-P. Meanwhile, nab-P also induced more peripheral sensory neuropathy. <b>Conclusion:</b> The two-weekly nab-P regimen is a good neoadjuvant chemotherapy choice for triple-negative breast cancer.